ストックスクリーナーアプリを入手
6.18
3.34%
0.20
アフターアワーズ：
6.18
Evolus Inc (EOLS) 最新ニュース
Evolus Inc (EOLS) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Evolus, Inc. Common Stock Revenue Breakdown – NASDAQ:EOLS - TradingView
Evolus Inc (EOLS) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Evolus, Inc. (EOLS) Q2 2023 Earnings ReportResults, Call & Slides - TipRanks
Evolus Inc (EOLS) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Evolus, Inc. (EOLS) Q2 2025 Earnings ReportResults, Call & Slides - TipRanks
Evolus Inc (EOLS) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Evolus, Inc. (EOLS) Q1 2024 Earnings ReportResults, Call & Slides - TipRanks
Press Release: Evolus to Report Second Quarter Financial Results on August 5, 2026 - Moomoo
Evolus to Report Second Quarter Financial Results on August 5, 2026 - Yahoo Finance
Evolus Inc. (EOLS) Slips 3.2% as Stock Approaches Key Support LevelCall Wall - dars.gov.et
Evolus, Inc. (EVL) Q2 2023 Earnings ReportResults, Call & Slides - TipRanks
Evolus, Inc. (EVL) Q3 2025 Earnings ReportResults, Call & Slides - TipRanks
Evolus, Inc. (EVL) Q2 2025 Earnings ReportResults, Call & Slides - TipRanks
Evolus, Inc. (EVL) Q1 2024 Earnings ReportResults, Call & Slides - TipRanks
Evolus, Inc. (EVL) Q3 2024 Earnings ReportResults, Call & Slides - TipRanks
(EOLS) and the Role of Price-Sensitive Allocations - Stock Traders Daily
Analysts Conflicted on These Healthcare Names: Irhythm Technologies (IRTC), Penumbra (PEN) and Evolus (EOLS) - The Globe and Mail
Evolus signs licensing deal for Profhilo skin injectable in US By Investing.com - Investing.com Nigeria
Evolus Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Business Wire
Evolus Class Action Reminder - TMX Newsfile
Analysts’ Top Healthcare Picks: Evolus (EOLS), Annovis Bio (ANVS) - The Globe and Mail
One Formula, One Platform: Inside the Preclinical Milestone Behind Conexeu's Move Into Medical Aesthetics - Finansavisen
ETFs Investing in Evolus, Inc. Stocks - TradingView
Evolus Lands Licensing Rights for Profhilo - Orange County Business Journal
Evolus, IBSA Partner to Develop and Commercialize Skin Quality Filler in the US - The Dermatology Digest
Evolus Partners with IBSA to Launch Profhilo® Injectable for Skin Quality in the U.S., Expanding Aesthetic Portfolio - Minichart
Evolus signs licensing deal for Profhilo skin injectable in US - Investing.com
Evolus Partners With IBSA to Develop, Commercialize Profhilo in US - Moomoo
Evolus Secures Exclusive U.S. Profhilo License From IBSA; No Upfronts, 15-Year Term - TradingView
Evolus Announces Partnership with IBSA to Develop and Commercialize Market-Leading Profhilo® in the United States, Expanding Its Injectable Portfolio into Skin Quality - Yahoo! Finance Canada
Needham Maintains Evolus(EOLS.US) With Hold Rating - Moomoo
Evolus (EOLS) Slides 0.86% as Stock Hovers Near Support – Market Sentiment Weighs on Aesthetics PlayerBeta Neutral Pair - dars.gov.et
EOLSEvolus Inc Options - Finviz
Evolus (EOLS) price target decreased by 11.11% to 14.96 - MSN
Evolus Q1 2026 earnings preview - MSN
Price to sales forward of Evolus, Inc. Common Stock – NASDAQ:EOLS - TradingView
Enterprise value to EBITDA forward of Evolus, Inc. Common Stock – NASDAQ:EOLS - TradingView
Enterprise value to revenue forward of Evolus, Inc. Common Stock – NASDAQ:EOLS - TradingView
Evolus, Inc. Actuals & Estimates (NASDAQ:EOLS) - TradingView
EVL Forecast — Price Target — Prediction for 2027 - TradingView
EOLS Forecast — Price Target — Prediction for 2027 - TradingView
Evolus Inc. (EOLS) Q1 2026 Earnings: EPS Surpasses Estimates, Signaling Operational ImprovementsEarnings Decline Risk - dars.gov.et
EOLS News | EVOLUS INC (NASDAQ:EOLS) - ChartMill
Evolus Inc (EOLS) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Evolus, Inc.(NasdaqGM: EOLS) added to S&P Pharmaceuticals Select Industry Index - marketscreener.com
Is Evolus (EOLS) Finally Turning the Corner on Profitability - Kavout | AI
Evolus Inc. Q1 2026 Earnings: EPS Surprises Sharply to the Upside as Investor Sentiment Stays MutedEarnings Momentum Score - dars.gov.et
EOLS Q1 2026 Earnings: EPS Beat Expectations Despite Narrow LossProfit Recovery Report - DonanımHaber
Evolus Inc (EOLS) Valuation: PE, PB & Fair Value Analysis - TradingKey
Evolus Inc (EOLS) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Evolus Inc (EOLS) Institutional Confidence - TradingKey
Evolus Inc (EOLS) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
BTIG Maintains Evolus(EOLS.US) With Buy Rating, Maintains Target Price $13 - Moomoo
EOLS Reiterated by BTIG -- Price Target Maintained at $13.00 - GuruFocus
[EFFECT] Evolus, Inc. SEC Filing - Stock Titan
0.30%
2.01%
大文字化:
|
ボリューム (24 時間):